이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

2026년 11월 19일 업데이트: ScandiBio Therapeutics AB

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Consenting participants will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 7 days prior to randomisation and start of investigational medicinal product (IMP) administration.

Eligible participants will be randomised on Day 1 (Visit 2) to 4 weeks of twice daily (b.i.d.) oral treatment of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The participants will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose.

Visits at the study site will be performed at Day 1 (Visit 2), Day 14 (Visit 4) and Day 28 (Visit 6; end of in study treatment). There will be telephone follow up visits at Day 7 (Visit 3) and Day 21(Visit 5) checking safety, concomitant medications and IMP compliance. A final follow-up visit for safety assessments will be conducted in a subgroup of patients 14 days after the end of treatment (Day 42; Visit 7) during an IMP-free follow-up period to assess safety and concomitant medications.

The following clinical scales will be used to evaluate the effect of CMA2 on uric acid decline, hsCRP and daily life activity: Serum Uric Acid Levels, hsCRP, number of flares according to the GAFFO criteria, HAQ-DI, SF-36, PGA (100 mm).

Plasma samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis.

Optionally, synovial samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis. Optionally, gut and saliva samples will be collected for metagenomics analysis of gut and oral microbiome.

Laboratory and clinical safety parameters will be monitored at pre-specified time-points.

연구 유형

중재적

등록 (추정된)

336

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Gökhan Gönenli, Uzm. Dr. M.
  • 전화번호: + 90 532 405 76 82
  • 이메일: mgonenli@ku.edu.tr

연구 연락처 백업

  • 이름: Müjdat Zeybel, Prof. Dr.
  • 전화번호: + 90 532 604 83 81
  • 이메일: mzeybel@ku.edu.tr

연구 장소

      • Ankara, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Ankara Bilkent City Hospital
        • 연락하다:
          • Hakan Babaoğlu
        • 수석 연구원:
          • Hakan Babaoğlu, Assoc. Prof. Dr.
      • Antalya, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Alanya Training and Research Hospital
        • 연락하다:
          • Şakir Özgür Keskek
        • 수석 연구원:
          • Şakir Özgür Keskek, Prof. Dr.
      • Erzurum, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Atatürk University Research Hospital
        • 연락하다:
          • Bülent Albayrak
        • 수석 연구원:
          • Bülent Albayrak, Assoc. Prof. Dr.
      • Erzurum, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Erzurum City Hospital
        • 연락하다:
          • Kenan Çadırcı
        • 수석 연구원:
          • Kenan Çadırcı, Prof. Dr.
      • Eskişehir, 터키 (Türkiye)
        • 모병
        • Eskişehir Osmangazi University Faculty of Medicine Hospital
        • 연락하다:
          • Nazife Şule Bige Yaşar
        • 수석 연구원:
          • Nazife Şule Bige Yaşar, Prof. Dr.
      • Istanbul, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Göztepe Prof. Dr. Süleyman Yalçın City Hospital
        • 연락하다:
          • Esen Kasapoğlu
        • 수석 연구원:
          • Esen Kasapoğlu, Prof. Dr.
      • Istanbul, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
        • 연락하다:
          • Gülen Hatemi
        • 수석 연구원:
          • Gülen Hatemi, Prof. Dr.
      • Istanbul, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Kanuni Sultan Süleyman Training and Research Hospital
        • 연락하다:
          • Ozan Cemal İçaçan
        • 수석 연구원:
          • Ozan Cemal İçaçan, Specialist. Dr.
      • Istanbul, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Kartal Dr. Lütfi Kırdar City Hospital
        • 연락하다:
          • Mehmet Engin Tezcan
        • 수석 연구원:
          • Mehmet Engin Tezcan, Specialist. Dr.
      • Istanbul, 터키 (Türkiye)
        • 모병
        • Koç University Hospital
        • 연락하다:
        • 수석 연구원:
          • Gökhan Gönenli, Specialist. Dr.
      • Istanbul, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
        • 연락하다:
          • Kadem Arslan
        • 수석 연구원:
          • Kadem Arslan, Assoc. Prof. Dr.
      • Istanbul, 터키 (Türkiye)
        • 아직 모집하지 않음
        • Sultan 2nd Abdülhamid Han Training and Research Hospital
        • 연락하다:
          • Memnune Sena Ulu
        • 수석 연구원:
          • Memnune Sena Ulu, Prof. Dr.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years.
  3. Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria.
  4. Able to give written informed consent for participation in the study by the patient and/or legal representatives.

Exclusion Criteria:

  1. Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion.

  2. Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period.

  3. History of stroke.

  4. History of brain trauma < 14 days.

  5. Uncontrolled diagnosed depression.

  6. Uncontrolled diabetes (HbA1c > 8.4%).

  7. Severe swallowing problems.

  8. PEG-feeding.

  9. Chronic diarrhoea.

  10. Chronic kidney disease with S-creatinine > 1.30 mg/dL.

  11. Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase

  12. Active bronchial asthma at the time of screening.

  13. History of phenylketonuria

  14. Known allergy for substances used in the study

  15. Known allergy for strawberry

  16. Known active malignancy

  17. Known active psoriasis

  18. Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.

  19. Use of anti-microbial agents later than one (1) week prior to inclusion.

  20. Drug and/or alcohol abuse.

  21. Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.

  22. Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

  23. Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)

  24. Females of childbearing potential who:

    Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device or intrauterine hormone-releasing system (IUS)
    • a contraceptive implant
    • an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
    • have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation.

    It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.

    NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).

  25. Male participants who:

    1. Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or
    2. Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product.
  26. Currently has secondary hyperuricemia:

1) Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study.

  • Dietary and physical therapy for the underlying disease
  • Drugs or containing compound preparations that potentially affect SUA level:
  • Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
  • Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
  • Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
  • Antihypertensives (losartan potassium)
  • Diuretics (thiazide diuretics, loop diuretics)
  • Sodium-dependent glucose transporter (SGLT) 2 inhibitors
  • Theophylline

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 치료 팔

A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

위약 비교기: 위약군

As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
기간: 4 weeks

Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).

4 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo.
기간: 4 weeks

Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity.

4 weeks
To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo.
기간: 4 weeks

Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment.

4 weeks
To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL.
기간: 4 weeks

Proportion of patients with a serum uric acid level <6 .0 mg/dL at end-of-treatment.

4 weeks
To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo.
기간: 2 weeks

Change in serum uric acid levels from baseline to 2-weeks.

2 weeks
To evaluate patient adherence to the twice-daily treatment regimen.
기간: 4 weeks

Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts.

4 weeks
To evaluate the incidence of adverse events (AEs).
기간: 6 weeks

The percentage of subjects experiencing at least one AE during the study period.

6 weeks
To evaluate the severity of AEs.
기간: 6 weeks

The incidence of AEs categorized by maximum severity grade.

6 weeks
To evaluate the incidence of serious adverse events (SAEs).
기간: 6 weeks

The percentage of subjects experiencing at least one SAE during the study period.

6 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Gökhan Gönenli, Uzm. Dr. M., Koc University Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 11월 4일

기본 완료 (추정된)

2027년 2월 1일

연구 완료 (추정된)

2027년 2월 1일

연구 등록 날짜

최초 제출

2026년 10월 15일

QC 기준을 충족하는 최초 제출

2026년 10월 15일

처음 게시됨 (실제)

2026년 10월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 19일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SB-GOUT-001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .